To understand the clinical impacts on targeting SET/PP2A/p-Akt signaling in NSCLC patients, we examined the expression of p-Akt and explored it relationship with SET expression in tumor tissues. This evidence concerns the gene PTPA and non-small cell lung carcinoma.